Audax Bio

Audax Bio is a preclinical-stage biotechnology company focused on engineering next-generation adeno-associated virus (AAV) vectors for gene therapy. Headquartered in Cambridge, Massachusetts, the company leverages a proprietary platform that integrates directed evolution with machine learning to design optimized AAV capsids. These engineered vectors are intended to address key challenges in the field, such as tissue specificity, pre-existing immunity, and manufacturing efficiency. Audax Bio was co-founded by prominent AAV researchers David Schaffer and Dirk Grimm, and it is backed by leading life sciences investors including 5AM Ventures. The company's technology aims to expand the reach of gene therapies to a broader range of diseases and patient populations.